脾酪氨酸激酶抑制可有效治疗已建立的血管炎临床前模型
该研究在Wistar Kyoto大鼠实验性自身免疫性血管炎模型中,探讨脾酪氨酸激酶(SYK)在ANCA相关血管炎发病中的作用。结果显示,发病后使用fostamatinib治疗14天可快速缓解尿检异常、改善肾肺病理并保护肾功能,且患者ANCA相关肾小球肾炎病变中可见SYK表达,提示SYK抑制值得临床研究。
要点
- SYK在实验性自免疫性血管炎早期炎症肾肺组织中表达上调。
- 发病后fostamatinib治疗14天可快速缓解尿检异常并改善肾肺病理。
- 患者ANCA相关肾小球肾炎炎症病变中可见SYK表达于CD68+单核/巨噬细胞。
核心结论
- SYK抑制在实验性自免疫性血管炎中有效,值得在ANCA相关血管炎治疗中开展临床研究。
研究设计与样本
- 临床前研究,采用Wistar Kyoto大鼠实验性自免疫性血管炎模型(髓过氧化物酶-ANCA诱导的寡免疫系统性血管炎)。
主要发现
- 实验性自免疫性血管炎早期炎症肾和肺组织中SYK表达上调,经免疫组化和转录分析证实。
- R406(fostamatinib的活性代谢物)在体外抑制大鼠白细胞中ANCA诱导的促炎反应。
- 发病后fostamatinib治疗14天,尿检异常快速缓解,肾和肺病理显著改善,肾功能得以保护。
- 短期fostamatinib暴露未显著影响循环髓过氧化物酶-ANCA水平。
- 患者ANCA相关肾小球肾炎的炎症肾小球病变中可见SYK表达,尤其位于CD68+单核/巨噬细胞内。
临床怎么用
- SYK抑制可作为ANCA相关血管炎治疗的潜在新靶点,但尚需临床研究验证。
局限性
- 研究为临床前动物模型,结果不能直接推广至人类患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are a group of life-threatening multi-system diseases characterized by necrotising inflammation of small blood vessels and crescentic glomerulonephritis. ANCA are thought to play a direct pathogenic role. Previous studies have shown that spleen tyrosine kinase (SYK) is phosphorylated during ANCA-induced neutrophil activation in vitro. However, the role of SYK in vivo is unknown. Here, we studied its role in the pathogenesis of experimental autoimmune vasculitis, a pre-clinical model of myeloperoxidase-ANCA-induced pauci-immune systemic vasculitis in the Wistar Kyoto rat. Up-regulation of SYK expression in inflamed renal and pulmonary tissue during early autoimmune vasculitis was confirmed by immunohistochemical and transcript analysis. R406, the active metabolite of fostamatinib, a small molecule kinase inhibitor with high selectivity for SYK, inhibited ANCA-induced pro-inflammatory responses in rat leucocytes in vitro. In an in vivo study, treatment with fostamatinib for 14 days after disease onset resulted in rapid resolution of urinary abnormalities, significantly improved renal and pulmonary pathology, and preserved renal function. Short-term exposure to fostamatinib did not significantly affect circulating myeloperoxidase-ANCA levels, suggesting inhibition of ANCA-induced inflammatory mechanisms in vivo. Finally, SYK expression was demonstrated within inflammatory glomerular lesions in ANCA-associated glomerulonephritis in patients, particularly within CD68+ve monocytes/macrophages. Thus, our data indicate that SYK inhibition warrants clinical investigation in the treatment of AAV.
引用
- McAdoo SP, Prendecki M, Tanna A, et al. Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model. Kidney Int. 2020. PMID: 32305129. doi:10.1016/j.kint.2019.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。